BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression

참고문헌 (49)

1. Schadendorf, D., "Melanoma", Lancet, 392, pp.971~984 (2018)
2. Deng, G., "EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma", Clin. Transl. Med, 12, pp.e722~ (2022)
3. Luebker, S. A., "Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies", Front. Oncol, 9, pp.268~ (2019)
4. Song, C., "Recurrent tumor cell-intrinsic and-extrinsic alterations during MAPKi-induced melanoma regression and early adaptation", Cancer Discov, 7, pp.1248~1265 (2017)
5. Curti, B. D., "Recent advances in the treatment of melanoma", N. Engl. J. Med, 384, pp.2229~2240 (2021)
6. Shin, D. S., "Primary resistance to PD-1 blockade mediated by JAK1", 2mutations, 2017, pp.7, 188~201
7. Zaretsky, J. M., "Mutations associated with acquired resistance to PD-1blockade in melanoma", N. Engl. J. Med, 375, pp.819~829 (2016)
8. Segura, M. F., "BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy", Cancer Res, 73, pp.6264~6276 (2013)
9. Yin, M., "Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction", Nat. Commun, 11, pp.1833~ (2020)
10. Deng, G., "BET inhibitor suppresses melanoma progression via the noncanonical NF-kappaB", SPP1 pathway, 2020, pp.10, 11428~11443
11. Yang, L., "Repression of BET activity sensitizes homologous recombinationproficient cancers to PARP inhibition", Sci. Transl. Med, 9, pp.eaal1645~ (2017)
12. Kanojia, D., "BET inhibition increases betaIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine", Sci. Transl. Med, 12, pp.eaax2879~ (2020)
13. Echevarria-Vargas, I. M., "Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma", Embo. Mol. Med, 10, pp.e8446~ (2018)
14. Fallahi-Sichani, M., "Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state", Mol. Syst. Biol, 13, pp.905~ (2017)
15. Korkut, A., "Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells", Elife, 4, pp.e04640~ (2015)
16. Paoluzzi, L., "BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma", Cancer Med, 5, pp.1183~1193 (2016)
17. Tiago, M., "Targeting BRD", BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF, Br. J. Cancer, pp.2020, 122[DOI]
18. Zhao, B., "The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma", Melanoma Res, 28, pp.521~526 (2018)
19. Emran, A. A., "A combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma", J. Invest. Dermatol, 141, pp.2238~2249 (2021)
20. Li, H., "The beneficial role of sunitinib in tumor immune surveillance by regulating tumor PD-L1", Adv. Sci. (Weinh. ), 8, pp.2001596~ (2021)
21. Kuang, X., "Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0", G1, Oncotarget, pp.2018, 9[DOI]
22. Deng, G., "BECN2(beclin 2)negatively regulates inflammasome sensors through ATG9A-dependent but ATG16L1-and LC3-independent non-canonical autophagy", Autophagy, 18, pp.340~356 (2022)
23. Simpkins, F., "Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells", Clin. Cancer Res, 24, pp.4874~4886 (2018)
24. Enserink, J. M., "Cell cycle-dependent transcription : the cyclin dependent kinase Cdk1 is a direct regulator of basal transcription machineries", Int. J. Mol. Sci, 23, pp.1293~ (2022)
25. Borlado, L. R., "CDC6 : from DNA replication to cell cycle checkpoints and oncogenesis", Carcinogenesis, 29, pp.237~243 (2008)
26. Bai, L., "A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo", Cancer Cell, 36, pp.498~511 (2019)
27. Zhao, Y., "Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma", Cell Biol. Toxicol, 37, pp.97~111 (2021)
28. Zhou, C., "Down-regulation of STAT3 induces the apoptosis and G1 cell cycle arrest in esophageal carcinoma ECA109 cells", Cancer Cell Int, 18, pp.53~ (2018)
29. Carson, R., "HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL", Clin. Cancer Res, 21, pp.3230~3240 (2015)
30. Jiang, X., "The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition", Clin. Cancer Res, 19, pp.598~609 (2013)
31. Zhao, K., "Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3", Eur. J. Cancer, 165, pp.58~70 (2022)
32. Sun, H. Y., "Bromodomain and extraterminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers", World J. Gastrointest. Oncol, 14, pp.75~89 (2022)
33. Zhang, Z., "BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1", Theranostics, 6, pp.219~230 (2016)
34. Ambrosini, G., "Inhibition of NF-kappaB-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma", Cancer Res, 79, pp.2415~2425 (2019)
35. Chua, V., "Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma", Embo. Mol. Med, 11, pp.e9081~ (2019)
36. Minor, D. R., "Sunitinib therapy for melanoma patients with KIT mutations", Clin. Cancer Res, 18, pp.1457~1463 (2012)
37. Finke, J. H., "Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients", Clin. Cancer Res, 14, pp.6674~6682 (2008)
38. Ko, J. S., "Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients", Clin. Cancer Res, 15, pp.2148~2157 (2009)
39. Wang, D., "GDF15 : emerging biology and therapeutic applications for obesity and cardiometabolic disease", Nat. Rev. Endocrinol, 17, pp.592~607 (2021)
40. Kluger, H. M., "Plasma markers for identifying patients with metastatic melanoma", Clin. Cancer Res, 17, pp.2417~2425 (2011)
41. Weide, B., "High GDF-15 serum levels independently correlate with poorer overall survival of patients with tumor-free stage III and unresectable stage IV melanoma", J. Invest. Dermatol, 136, pp.2444~2452 (2016)
42. Nakayasu, E. S., "Comprehensive proteomics analysis of stressed human islets identifies GDF15 as a target for type 1 diabetes intervention", Cell Metab, 31, pp.363~374 (2020)
43. Kempf, T., "The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia", reperfusion injury, 2006, pp.98, 351~360
44. Liu Yongshi, "Knockdown of growth differentiation factor-15 inhibited nonsmall cell lung cancer through inactivating PTEN", PI3K, Genes & Genomics, pp.2023, 45(4)[DOI]
45. Chen, L., "Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K", AKT, PPARgamma signaling pathway, pp.Ann. Transl. Med, 2021[DOI]
46. Guo, L. L., "Downregulated long noncoding RNA GAS5 fails to function as decoy of CEBPB, resulting in increased GDF15 expression and rapid ovarian cancer cell proliferation", Cancer Biother. Radiopharm, 34, pp.537~546 (2019)
47. Lee, J., "Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization", Melanoma Res, 32, pp.1~10 (2022)
48. Xin, H., "Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells", Cancer Res, 69, pp.2506~2513 (2009)
49. Guo, F., "NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15", Cell Death Discov, 7, pp.78~ (2021)

관련 논문AI추천